Doc Logic, I’m still invested in the biotech that had to sell that basis of celgene’s success to celgene. That company was Enmed and is now Casi with different management and game plan today, trying to build a successful business acquiring cancer drugs to seek approval and sell in the Chinese market.
They had another kinase inhibitor drug that they were trying to take through the clinical development process that had shown promise in mouse models and Petri dishes I believe. Current management greatly deemphasized that candidate and is capitalizing on being able to get existing drugs to be approved in China where there apparently is great need for cancer treatments. I believe they just had their first positive quarter, fwiw.
Market Data 
Markets 
AI
